Skip to Content
  • The NIH Goes For the Gusto

    Here’s an interesting funding opportunity from NIH: Recent advances in neuroscience offer unprecedented opportunities to discover new treatments for nervo… Read More
  • Value in Structure?

    A friend on the computational/structural side of the business sent along this article from Nature Reviews Drug Discovery. The authors are looking through the Th… Read More
  • More on KV and Makena’s Pricing

    I wanted to do some follow-up on the Makena story – the longtime progesterone ester drug that has now been newly FDA-approved and newly made two order of… Read More
  • Makena’s Price: What to Do?

    The situation with KV Pharmaceuticals and the premature birth therapy Makena has been all over the news in the last couple of days. Briefly, Makena is an inject… Read More
  • That $43 Million R&D Figure

    One of the readers in the comments section to the last post noticed Rebecca Warburton trying to clarify that absurd $43-million-per-drug R&D figure. You… Read More
  • Down In Phase III. Again.

    Past performance (Phase II results) are no guarantee of future success (Phase III). That warning has been proven over and over in this business, and an awful lo… Read More
  • New Cures! Faster! Faster!

    I wrote here the other day about the NIH’s new translational medicine plans. The New York Times article that brought this to wide attention didn’t g… Read More
Page 30 of 54« First...1020...2829303132...4050...Last »